1 / 44

Therapeutic Uses of Cannabis

Therapeutic Uses of Cannabis. B. Brands, Ph.D. Centre for Addiction and Mental Health Clinical Research Department Department of Pharmacology University of Toronto (Presented by Wende Wood, B.A., B.S.P., B.C.P.P. Drug Information and Drug Use Evaluation Pharmacist).

arlais
Download Presentation

Therapeutic Uses of Cannabis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Therapeutic Uses of Cannabis B. Brands, Ph.D. Centre for Addiction and Mental Health Clinical Research Department Department of Pharmacology University of Toronto (Presented by Wende Wood, B.A., B.S.P., B.C.P.P. Drug Information and Drug Use Evaluation Pharmacist)

  2. Excerpted from: Kalant, H. (2001) Medicinal use of cannabis: History and current status. Pain Res. Manage 6(2): 80-91. Other Sources: Baker et al (2003) The therapeutic potential of cannabis. The Lancet. Neurology 2: 291-298. Croxford, J.L. (2003) Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17(3): 179- 202. Joy, J.E. et al (1999) Marijuana and medicine: Assessing the science base. Washington, D.C., National Academy Press. Additional Reading: Bagshaw, S.M. (2002) Medical efficacy of cannabinoids and marijuana: A comprehensive review of the literature. Journal of Palliative Care 18(2) 111-122. Iverson, L. (2003) Cannabis and the Brain. Brain 126: 1252-1270.

  3. Kalant, 2001

  4. Mechanisms of Action

  5. Mechanisms of Action (cont’d)

  6. Location of Cannabinoid Receptors Croxford, JL. CNS Drugs 2003; 17(3)

  7. Baker et al, 2003

  8. receptors are linked to Gi protein • decrease adenylyl cyclase activity • prevent activation of various Ca2+ channels and activate K+ influx • major effect - decreased cell excitability • probably modify responses to various neurotransmitters, and  NT release

  9. Diagram of Neuron with Synapse Individual nerve cells, or neurons, both send and receive cellular signals to and from neighbouring neurons, but for the purposes of the previous diagram, only one activity is indicated for each cell. Neurotransmitter molecules are released from the neuron terminal and move across the gap between the ‘sending’ and ‘receiving’ neurons. A signal is transmitted to the receiving neuron when the neurotransmitters have bound to the receptor on its surface. From: Marijuana and Medicine: Assessing the Science Base, IOM 1999

  10. Relative Affinities of Various Cannabinoids for CB1 and CB2 Cannabinoid Receptors Kalant, 2001

  11. Possible Routes of Administration

  12. Possible Routes of Administration (cont’d) • IV - very low water solubility, requires special formulation - rapid onset of action - dosage limitations  short duration of effect • Smoking - rapid absorption (like IV) - bioavailability 18-50% - high variability due to smoking techniques • Topical - very limited applicability

  13. Metabolic Disposition

  14. Metabolic Disposition (cont’d)

  15. Major Metabolic Pathway

  16. Pharmacological Effects

  17. Pharmacological Effects (cont’d) Acute Effects • Pain perception ↓ (exerted at CB1 receptor) • Antinauseant and antiemetic effects, ↑ appetite (CB1 receptors) • Anticonvulsant effects (not via CB1 receptors)

  18. Pharmacological Effects (cont’d)

  19. Pharmacological Effects (cont’d) Respiratory • Bronchodilation → ↓ airway resistance (acute) • Bronchial irritation → particulate fraction of cannabis smoke (chronic) • Cannabis smoke similar to tobacco smoke Eye • ↓ IOP at doses that produce CNS effects Immune System • Effects unclear

  20. Chronic Effects • CNS • cognitive changes include poor memory, vagueness of thought, decreased verbal fluency, learning deficits • daily high doses can cause chronic intoxication syndrome (apathy), confusion, depression, paranoia • cannabis dependence (DSM-IV criteria)

  21. Chronic Effects (cont’d) • Respiratory System • ↑ chronic inflammatory chest disease • precancerous changes

  22. Modern Scientific Research on Cannabis

  23. Modern Scientific Research on Cannabis (cont’d)

  24. Actual and Potential Medical Uses

  25. Actual and Potential Medical Uses (cont’d) • Modern western medicine: • Accepted uses • – antinauseant, antiemetic • – appetite stimulant • – cancer chemotherapy, AIDS • Possible uses worth study: • – analgesia • – antispasticity (e.g. multiple sclerosis) • – immunosuppressant • – glaucoma • – anticonvulsant, mainly cannabidiol, not THC

  26. Recent Clinical Trials of Cannabinoids for the Treatment of CNS Disorders CBD = cannabidiol THC = tetrahydrocannabinol Croxford, JL. CNS Drugs 2003; 17(3)

  27. Recent Clinical Trials of Cannabinoids for the Treatment of CNS Disorders (cont’d) Croxford, JL. CNS Drugs 2003; 17(3)

  28. Analgesia • CB1-selective agonists reduce pain • receptors in periaqueductal gray mainly (direct local injection effective) • separate from opioid analgesia mechanism • naloxone blocks morphine analgesia but not THC analgesia • CB1 blocker (SR 141716A) blocks THC but not morphine analgesia • but THC and morphine augment each other’s effects - possibility of combined use

  29. Analgesia (cont’d) • both oral THC and smoked marijuana work • onset of action faster with smoking • for chronic pain, speed not necessary • new water-soluble esters of THC-acid analogs • analgesic and anti-inflammatory action • no psychoactivity, no gastric irritation • possible replacement for NSAIDs? • migraine – only anecdotal evidence • no controlled comparison of oral vs smoked

  30. Relief of Spasticity (e.g., Multiple Sclerosis)

  31. Relief of Spasticity (e.g., Multiple Sclerosis)

  32. Glaucoma

  33. Glaucoma (cont’d)

  34. Potential Adverse Effects of Cannabinoid Therapy Croxford, JL. CNS Drugs 2003; 17(3)

  35. Problems in Design of Clinical Trials • Almost no data on pharmacokinetics during chronic treatment – long t½ means risk of accumulation – need to monitor residual levels regularly • Distribution between plasma and tissues may invalidate ordinary methods for measurement of bioavailability

  36. Problems in Design of Clinical Trials

  37. Problems in Design of Clinical Trials

  38. Problems in Design of Clinical Trials

  39. Problems in Design of Clinical Trials

  40. Problems in Design of Clinical Trials

  41. Considerations in Use of Crude Cannabis versus Pure Cannabinoids • adequate control of dosage • smoking more variable unless tightly controlled • available routes of administration • cannabis: smoked or ingested • pure THC or cannabinoids: oral, rectal, aerosol inhalation, topical • selectivity of therapeutic action • better promise with synthetic derivatives (receptor selectivity)

  42. Considerations in Use of Crude Cannabis versus Pure Cannabinoids (cont’d)

  43. Historical Comparisons between Cannabinoids and Opioids

More Related